Delcath Systems, Inc. · NASDAQ:DCTH
Delcath Systems — American Hepato-Pancreato-Biliary Association Annual Meeting 2008
23 slides from Delcath Systems's conference presentation, Mar 29, 2008
Slide 1: High Dose Intra-Arterial Melphalan Delivered via Percutaneous Hepatic Perfusion
High Dose Intra-Arterial Melphalan Delivered via Percutaneous Hepatic Perfusion (PHP) for Patients with Unresectable Hepatic Metastases from Primary Neuroendocrine Tumors. James F. Pingpank, Richard E. Royal, Udai S. Kammula, Anthony W. Kam, Bradford J. Wood, H. Richard Alexander, Steven K. Libutti
Slide 2: Disclosures
Disclosures This research is supported by NCI Intramural Research funding and an extensive CRADA agreement between Delcath Systems, Inc. and the Surgery Branch of the NCI. Delcath double balloon catheter under IDE Intra-arterial melphalan and Delcath catheter under IND
Slide 3: Malignant Neuroendocrine Tumors
Malignant Neuroendocrine Tumors Well-Differentiated Pancreatic Endocrine Neoplasms Patients: n=183, (166 rendered NED at surgical resection) Hepatic Recurrence (first site): n=22 (76%) (Ferrone/Allen, MSKCC: JCO 2007 (25):5609) Non-Functional PNET 2.6-3.0 cases/million population At diagnosis: Node
Slide 4: Survival Following Hepatic Metastasectomy for Non-Colorectal Histologies
Survival Following Hepatic Metastasectomy for Non-Colorectal Histologies Actuarial Median Survival Author Histology N 5-yr Survival (Months) Chen et al Neuroendocrine 15 73% NR Que et al Neuroendocrine 74 73% NR Harrison et al Genitourinary 34 60% NR Jaques et al Sarcoma 14 0% 30 Harrison et al Brea
Slide 5: Management of bilobar liver metastases
Management of bilobar liver metastases Carcinoid Metastases: Hepatic Artery Chemoembolization (Bloomston, OHSU: JGISurg 2007 (11): 264) Patients: n=122 Response: Radiographic (82%), Biochemical (74%), Symptomatic (92%) Median Hepatic Progression-Free Survival: 10.0 months Median Overall Survival: 33
Slide 6: Rationale for Regional Therapy
Rationale for Regional Therapy Regional therapy allows dose escalation to the cancer-bearing region or organ of the body while minimizing systemic exposure and toxicity, via complete separation of the regional and systemic circulation Eliminates or significantly reduces systemic toxicity, and dose e
Slide 7: Isolated Hepatic Perfusion Overall Survival
Isolated Hepatic Perfusion Overall Survival (n=17) 1.0 0.8 Overall Response: 53% Percentage Surviving Median: 52m 0.6 17 Treated, 10 Died 0.4 0.2 0.0 0 20 40 60 80 100 120 Survival (Months) Isolated Hepatic Perfusion Circuit Surgery 2004;136:1176-82. (Updated March, 2008)
Slide 8: Percutaneous Hepatic Perfusion
Percutaneous Hepatic Perfusion
Slide 9: Methods
Methods All patients treated on an NCI IRB approved phase I or phase II protocol utilizing PHP with Melphalan Inclusion Criteria: Non resectable hepatic metastases Limited, treatable (resection/xrt) extra-hepatic disease Adequate hepatic reserve (Bili<3.0, PT w/in 2 seconds of normal, LFTs <10x ULN)
Slide 10: PHP Patient Demographics
PHP Patient Demographics Neuroendocrine Tumors (n=23) Median no. of hepatic lesions 15 Mean diameter of largest lesion 4.8 cm Extrahepatic Disease 9 (39%) Subsequent Resection: n=7 Percentage hepatic replacement <25% 12 (52%) 25-50% 5 (22%) >50% 6 (26%) Primary Tumor Histology Carcinoid 6 PNET 17
Slide 11: Protocol Schema
Protocol Schema On Study Evaluation Interval Evaluation Post Treatment Evaluation Treatments 1 and 2 Treatments 3 and 4 - Melphalan - Melphalan - Angiogram (Celiac, SMA) - Angiogram (Celiac, SMA) - GDA assessment (Treatment #1) - GDA assessment 4-5 Weeks 4-5 Weeks 4-5 Weeks 4-5 Weeks 16 weeks
Slide 12: PHP Response: Neuroendocrine Tumors
PHP Response: Neuroendocrine Tumors (n=23) NE (Toxicity*, Incomplete Tx, OLT) 4 PD at interval evaluation 1 SD/MR 3 PR 13 CR 2 Overall Response Rate (19 patients) 15 (79%) 100 80 60 Maximum response 40 20 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 -20 -40 -60 -80 -100 Patients
Slide 13: PHP Response and Results: Neuroendocrine Tumors
PHP Response: Neuroendocrine Tumors (n=23) NE (Toxicity*, Incomplete Tx, OLT) 4 PD at interval evaluation 1 SD/MR 3 PR 13 CR 2 Overall Response Rate (19 patients) 15 (79%) PHP Results: Neuroendocrine Tumors (68 Treatments) Mean Melphalan Dose at 3.0 mg/kg: 180 mg (126-220) Unsuccessful Therapy Scler
Slide 14: Procedure and Treatment Related Toxicities
Procedure and Treatment Related Toxicities (68 Procedures; March 2008) Procedure Related Complications N Carcinoid Crisis 1 CNS Tumor Hemorrhage (Grade 3) 1 Tumor Lysis Syndrome (Grade 3) 1 Treatment Related Toxicity, Grade 3-4 (n,%) Hematologic Early (n=68) Late (n=68) Neutropenia 0 32 (47%) Thromb
Slide 15: Procedure and Treatment Related Toxicities
Procedure and Treatment Related Toxicities (68 Procedures; March 2008) Procedure Related Complications N Carcinoid Crisis 1 CNS Tumor Hemorrhage (Grade 3) 1 Tumor Lysis Syndrome (Grade 3) 1 Treatment Related Toxicity, Grade 3-4 (n,%) Hematologic Early (n=68) Late (n=68) Neutropenia 0 32 (47%) Thromb
Slide 16: Procedure and Treatment Related Toxicities
Procedure and Treatment Related Toxicities (68 Procedures; March 2008) Procedure Related Complications N Carcinoid Crisis 1 CNS Tumor Hemorrhage (Grade 3) 1 Tumor Lysis Syndrome (Grade 3) 1 Treatment Related Toxicity, Grade 3-4 (n,%) Hematologic Early (n=68) Late (n=68) Neutropenia 0 32 (47%) Thromb
Slide 17: Procedure and Treatment Related Toxicities
Procedure and Treatment Related Toxicities (68 Procedures; March 2008) Procedure Related Complications N Carcinoid Crisis 1 CNS Tumor Hemorrhage (Grade 3) 1 Tumor Lysis Syndrome (Grade 3) 1 Treatment Related Toxicity, Grade 3-4 (n,%) Hematologic Early (n=68) Late (n=68) Neutropenia 0 32 (47%) Thromb
Slide 18: Hepatic Progression-Free Survival After PHP
Hepatic Progression-Free Survival After PHP Metastatic Neuroendocrine Tumor (n=20) 1.0 Median: 39 months 20 Treated 0.9 Censored for death from extra-hepatic disease (n=4) 0.8 Not Evaluable due to hepatic toxicity (n=1) On Active Treatment (n=2) 0.7 Proportion Surviving 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0
Slide 19: Overall Survival After PHP
Overall Survival After PHP Metastatic Neuroendocrine Tumor (n=23) 1.0 Cause of Death 0.9 Extrahepatic disease (n=2) 0.8 Systemic/liver disease (n=2) Hepatic Progression (n=1) 0.7 Proportion Surviving Toxicity (n=1) 0.6 0.5 Median: 40 months 0.4 23 Treated Patients 0.3 0.2 0.1 0.0 0 12 24 36 48 60 Su
Slide 20: Conclusions
Conclusions High-dose Melphalan, delivered via intra-arterial administration is effective against hepatic metastases from neuroendocrine tumors Tumor reduction from PHP routinely results in durable control of hormone-related symptoms An expanded, phase II multi-center confirmatory trial is planned,
Slide 21: Metastatic Glucagonoma
Metastatic Glucagonoma 54 year-old female Metastatic pancreatic neuroendocrine tumor Primary in place, treated post PHP with XRT PHP#1 PHP#2 XRT Pancreas Bed
Slide 22: Chemotherapy Levels During Therapy: PHP vs Systemic
Chemotherapy Levels During Therapy PHP vs Systemic Hepatic Arterial Infusion with Venous Filtration (Patient: William A, 3/4/03, 3 mg/kg, 178 mg) 20 Melphalan Concentration (g/ml) infusion Periphery Artery Pre-filter Post-filter 15 .20 mg/kg 10 3.0 mg/kg 5 0 0 10 20 30 40 50 60 70 Time (min) Percut
Slide 23: Management of Liver Metastases from Neuroendocrine Tumors
Management of Liver Metastases from Neuroendocrine Tumors 48 patients Carcinoid (n=36), Islet Cell (n=12) Therapy (non-randomized) Resection/Ablation: 13 pts Chemo-embolization: 18 pts Conservative therapy: 17 pts No difference in volume of hepatic disease No difference in symptom palliation Arch Su
Delcath Systems — American Hepato-Pancreato-Biliary Association Annual Meeting 2008 on 6ix